<DOC>
	<DOC>NCT00109096</DOC>
	<brief_summary>The purposes of this study are to determine: - whether standard or higher doses of pemetrexed should be given to patients with ovarian or primary peritoneal cancer that has recurred; - the safety and side effects of standard and higher doses of pemetrexed given to patients with ovarian or primary peritoneal cancer that has recurred; - whether standard or higher doses of pemetrexed can help patients with ovarian or primary peritoneal cancer that has recurred.</brief_summary>
	<brief_title>Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patient must have been diagnosed with ovarian or primary peritoneal cancer Patient must have had 1 or 2 prior platinumbased chemotherapeutic regimens. Patient must have adequate health status. Patient compliance and geographic proximity that allow for adequate follow up is required. Signed informed consent from the patient or legal representative is required. Patient is pregnant or breastfeeding Patient has received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. Patient has previously participated in another study investigating pemetrexed. Patient is unable or unwilling to take folic acid, vitamin B12 supplementation, and corticosteroids. Patient cannot be taking nonsteroidal antiinflammatory drugs around the time of administration of study drug.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>